Bone Abstracts

Introduction: We aimed to study acceptability of zoledronic acid in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, biochemical, shipping registration at poll by phone and on the subsequent visits.Results: We studied 225 patients with postmenopausal osteoporosis. The patients were treated with zoledronic acid (Zol) 5 mg as a once-yearly infusion within 3 years and 2500 mg of calcium carbonate+800 ME v...

Introduction: We aimed to study efficacy of zoledronic acid (Zol) in the treatment of postmenopausal osteoporosis within 3 years.Methods: Clinical, bone mineral density (BMD) by DEXA (L1–L4, femoral Neck) (baseline, 12, 24, and 36 months); biochemical; immunoenzyme assay of bone turnover markers (BTM) – osteocalcin (OK) β-C-terminal telopeptides of type 1 collagen (CTX) (baseline, 1, 3, 6, 9, and 12 after one, two, three infusions).<p ...

Research design and methods: A characterisation of 225 European (Russian) osteoporotic postmenopausal women, treated for 2 years with amino-bisphosphonate zoledronic acid (zol), with respect to the adenosine/cytosine (A/C) rs2297480 farnesyl pyrophosphate synthase (FDPS) gene polymorphism, was carried out by PCR-based enzymatic digestion and quantitative PCR allelic discrimination on genomic DNA extracted from blood leukocytes. The association between these polymorphism genoty...